Amarin Corp. PLC ADR | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
192,512.90
119,149.20
107,560.70
99,894.00
74,237.00
250,727
Total Accounts Receivable
3,645.00
7,777.40
13,826.00
20,195.90
45,318.00
66,523
Inventories
21,208.90
13,619.90
18,984.90
20,723.40
30,260.00
57,802
Other Current Assets
2,034.00
3,537.60
3,152.00
7,056.70
3,455.00
2,945
Total Current Assets
219,400.70
144,084.00
143,523.60
147,870.00
153,270.00
377,997
Net Property, Plant & Equipment
579.00
377.90
243.00
78.80
28.00
63
Intangible Assets
10,708.90
9,980.10
9,417.00
8,864.60
8,126.00
7,480
Other Assets
9,841.90
2,802.70
174.00
748.80
174.00
174
Total Assets
252,474.50
169,697.20
173,229.50
169,822.20
163,335.00
385,714
ST Debt & Current Portion LT Debt
6.00
15,267.20
14,742.00
31,625.20
22,829.00
Accounts Payable
6,375.00
8,454.80
10,832.00
6,126.00
25,155.00
Other Current Liabilities
31,158.80
16,252.00
25,148.90
39,302.40
60,546.00
Total Current Liabilities
37,539.80
39,973.90
50,722.80
77,053.60
108,530.00
Long-Term Debt
248,136.50
217,059.80
236,415.30
86,053.50
99,826.00
Deferred Taxes
11,943.90
12,452.60
19,871.90
11,198.90
-
Other Liabilities
654.00
382.80
13,643.00
14,807.60
18,342.00
Total Liabilities
286,330.30
257,416.50
300,781.10
178,975.80
228,435.00
Common Equity (Total)
33,855.80
87,719.30
151,915.50
33,774.70
89,464.00
Total Shareholders' Equity
33,855.80
87,719.30
127,551.60
9,153.60
65,100.00
Total Equity
33,855.80
87,719.30
127,551.60
9,153.60
65,100.00
Liabilities & Shareholders' Equity
252,474.50
169,697.20
173,229.50
169,822.20
163,335.00
Preferred Stock (Carrying Value)
-
-
24,363.90
24,621.10
24,364.00

About Amarin Corp.

View Profile
Address
2 Pembroke House
Dublin Dublin 2
Ireland
Employees -
Website http://amarincorp.com
Updated 07/08/2019
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It's product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.